UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 31, 2024
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM __________ TO __________
COMMISSION FILE NUMBER: 000-54437
SUNHYDROGEN, INC.
(Name of registrant in its charter)
Nevada | | 26-4298300 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer
Identification No.) |
BioVentures Center, 2500 Crosspark Road, Coralville, IA 52241 |
(Address of principal executive offices) (Zip Code) |
Issuer’s telephone Number: (805) 966-6566
Former address, if changed since last report
Securities registered pursuant
to Section 12(b) of the Act:
Title of each class |
|
Ticker symbol(s) |
|
Name of each exchange on which registered |
N/A |
|
N/A |
|
N/A |
Indicate by check mark whether
the registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether
the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files). Yes ☒ No ☐
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting
company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ |
Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| | Emerging growth company | ☐ |
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether
the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐
No ☒
The number of shares of registrant’s
common stock outstanding, as of February 10, 2025 was 5,437,338,655.
SUNHYDROGEN, INC.
INDEX
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
SUNHYDROGEN, INC.
CONDENSED BALANCE SHEETS
| |
December 31, | | |
June 30, | |
| |
2024 | | |
2024 | |
| |
(unaudited) | | |
| |
ASSETS | |
| | |
| |
CURRENT ASSETS | |
| | |
| |
Cash and cash equivalents | |
$ | 39,631,955 | | |
$ | 39,044,795 | |
Prepaid expenses | |
| 164,585 | | |
| - | |
Equity securities, related party | |
| - | | |
| 4,101,402 | |
| |
| | | |
| | |
TOTAL CURRENT ASSETS | |
| 39,796,540 | | |
| 43,146,197 | |
| |
| | | |
| | |
OTHER ASSETS | |
| | | |
| | |
| |
| | | |
| | |
PROPERTY & EQUIPMENT | |
| | | |
| | |
Machinery and equipment | |
| 36,830 | | |
| 36,830 | |
Computers and peripherals | |
| 11,529 | | |
| 11,529 | |
Vehicle | |
| 135,260 | | |
| 135,260 | |
| |
| 183,619 | | |
| 183,619 | |
Less: accumulated depreciation | |
| (36,255 | ) | |
| (20,549 | ) |
| |
| | | |
| | |
NET PROPERTY AND EQUIPMENT | |
| 147,364 | | |
| 163,070 | |
| |
| | | |
| | |
INTANGIBLE ASSETS | |
| | | |
| | |
Trademark, net of amortization of $885 and $827, respectively | |
| 257 | | |
| 315 | |
Patents, net of amortization of $46,191 and 42,909, respectively | |
| 54,952 | | |
| 58,234 | |
| |
| | | |
| | |
TOTAL INTANGIBLE ASSETS | |
| 55,209 | | |
| 58,549 | |
| |
| | | |
| | |
TOTAL OTHER ASSETS | |
| 202,573 | | |
| 221,619 | |
| |
| | | |
| | |
TOTAL ASSETS | |
$ | 39,999,113 | | |
$ | 43,367,816 | |
| |
| | | |
| | |
LIABILITIES, PREFERRED STOCK SUBJECT TO REDEMPTION AND SHAREHOLDERS’ DEFICIT | |
| | | |
| | |
| |
| | | |
| | |
CURRENT LIABILITIES | |
| | | |
| | |
Accounts payable and other payables | |
$ | 361,792 | | |
$ | 573,127 | |
Accrued expenses | |
| 161,497 | | |
| 140,558 | |
Loan payable, related party | |
| - | | |
| 45,829 | |
| |
| | | |
| | |
TOTAL LIABILITIES | |
| 523,289 | | |
| 759,514 | |
| |
| | | |
| | |
COMMIMENTS AND CONTINGENCIES | |
| - | | |
| - | |
| |
| | | |
| | |
Series C 10% Preferred Stock, 6,651 and 8,851 shares issued and outstanding, redeemable value of $665,100 and $885,100, respectively | |
| 665,100 | | |
| 885,100 | |
| |
| | | |
| | |
SHAREHOLDERS’ EQUITY | |
| | | |
| | |
Preferred Stock, $0.001 par value; 5,000,000 authorized preferred shares | |
| - | | |
| - | |
Common Stock, $0.001 par value; 10,000,000,000 authorized common shares 5,437,338,655 and 5,087,245,974 shares issued and outstanding, respectively | |
| 5,437,339 | | |
| 5,087,246 | |
Additional Paid in Capital | |
| 130,743,528 | | |
| 128,488,199 | |
Accumulated deficit | |
| (97,370,143 | ) | |
| (91,852,243 | ) |
| |
| | | |
| | |
TOTAL SHAREHOLDERS’ EQUITY | |
| 38,810,724 | | |
| 41,723,202 | |
| |
| | | |
| | |
TOTAL LIABILITIES, PREFERRED STOCK SUBJECT TO REDEEMPTION AND SHAREHOLDERS’ EQUITY | |
$ | 39,999,113 | | |
$ | 43,367,816 | |
The
accompanying notes are an integral part of these unaudited condensed financial statements.
SUNHYDROGEN, INC.
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
| |
Three Months Ended
December 31, | | |
Six Months Ended
December 31, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
| |
| | |
| | |
| | |
| |
REVENUE | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | | |
| | |
OPERATING EXPENSES | |
| | | |
| | | |
| | | |
| | |
Selling and Marketing | |
| 323 | | |
| - | | |
| 647 | | |
| 44,000 | |
General and administrative expenses | |
| 621,609 | | |
| 497,844 | | |
| 1,040,353 | | |
| 1,002,505 | |
Research and development cost | |
| 626,318 | | |
| 756,263 | | |
| 1,234,323 | | |
| 1,195,327 | |
Depreciation and amortization | |
| 9,692 | | |
| 10,775 | | |
| 19,046 | | |
| 21,780 | |
| |
| | | |
| | | |
| | | |
| | |
TOTAL OPERATING EXPENSES | |
| 1,257,942 | | |
| 1,264,882 | | |
| 2,294,369 | | |
| 2,263,612 | |
| |
| | | |
| | | |
| | | |
| | |
LOSS FROM OPERATIONS BEFORE OTHER INCOME (EXPENSES) | |
| (1,257,942 | ) | |
| (1,264,882 | ) | |
| (2,294,369 | ) | |
| (2,263,612 | ) |
| |
| | | |
| | | |
| | | |
| | |
OTHER INCOME/(EXPENSES) | |
| | | |
| | | |
| | | |
| | |
Investment income | |
| 439,645 | | |
| 484,984 | | |
| 919,368 | | |
| 960,593 | |
Dividend expense | |
| (39,565 | ) | |
| (22,591 | ) | |
| (40,871 | ) | |
| (43,520 | ) |
Unrealized (gain)/loss on change in fair value of investment, related party | |
| (2,613,117 | ) | |
| (2,224,504 | ) | |
| (4,101,402 | ) | |
| (1,938,835 | ) |
Realized gain(loss) on redemption of marketable securities | |
| - | | |
| - | | |
| - | | |
| (188,040 | ) |
Interest expense | |
| (83 | ) | |
| (1,714 | ) | |
| (626 | ) | |
| (3,405 | ) |
| |
| | | |
| | | |
| | | |
| | |
TOTAL OTHER INCOME (EXPENSES) | |
| (2,213,120 | ) | |
| (1,763,825 | ) | |
| (3,223,531 | ) | |
| (1,213,207 | ) |
| |
| | | |
| | | |
| | | |
| | |
NET INCOME (LOSS) | |
$ | (3,471,062 | ) | |
$ | (3,028,707 | ) | |
$ | (5,517,900 | ) | |
$ | (3,476,819 | ) |
| |
| | | |
| | | |
| | | |
| | |
BASIC & DILUTED EARNINGS (LOSS) PER SHARE | |
$ | (0.00 | ) | |
$ | (0.00 | ) | |
$ | (0.00 | ) | |
$ | (0.00 | ) |
| |
| | | |
| | | |
| | | |
| | |
WEIGHTED-AVERAGE COMMON SHARES
OUTSTANDING BASIC & DILUTED | |
| 5,303,929,044 | | |
| 5,069,670,749 | | |
| 5,203,191,703 | | |
| 4,965,620,378 | |
The accompanying notes are an integral part of these unaudited condensed financial statements.
SUNHYDROGEN, INC.
CONDENSED STATEMENTS OF SHAREHOLDER’S DEFICIT
FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2024 AND 2023
| |
| | |
| | |
| | |
| | |
| | |
Additional | | |
| | |
| |
| |
Preferred stock | | |
| | |
Common stock | | |
Paid-in | | |
Accumulated | | |
| |
| |
Shares | | |
Amount | | |
Mezzanine | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Total | |
Balance at June 30, 2023 | |
| - | | |
$ | - | | |
$ | 1,095,100 | | |
| 4,821,298,283 | | |
$ | 4,821,298 | | |
$ | 126,889,423 | | |
$ | (81,971,040 | ) | |
$ | 49,739,681 | |
Issuance of common stock upon partial conversion of purchase agreement for cash | |
| - | | |
| - | | |
| - | | |
| 18,684,057 | | |
| 18,684 | | |
| 225,291 | | |
| - | | |
| 243,975 | |
Issuance of common stock upon conversion of Series C Preferred stock | |
| - | | |
| - | | |
| (210,000 | ) | |
| 221,052,632 | | |
| 221,053 | | |
| (11,053 | ) | |
| - | | |
| 210,000 | |
Stock compensation expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 72,481 | | |
| - | | |
| 72,481 | |
Net Loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (448,112 | ) | |
| (448,112 | ) |
Balance at September 30, 2023 (unaudited) | |
| - | | |
| - | | |
| 885,100 | | |
| 5,061,034,972 | | |
| 5,061,035 | | |
| 127,176,142 | | |
| (82,419,152 | ) | |
| 49,818,025 | |
Issuance of common stock upon partial conversion of purchase agreement for cash | |
| - | | |
| | | |
| | | |
| 31,779,661 | | |
| 31,780 | | |
| 261,195 | | |
| - | | |
| 292,975 | |
Stock compensation expense | |
| - | | |
| | | |
| | | |
| - | | |
| - | | |
| 72,482 | | |
| - | | |
| 72,482 | |
Net Loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (3,028,707 | ) | |
| (3,028,707 | ) |
Balance at December 31, 2023 (unaudited) | |
| - | | |
| - | | |
| 885,100 | | |
| 5,092,814,633 | | |
| 5,092,815 | | |
| 127,509,819 | | |
| (85,447,859 | ) | |
| 47,154,775 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance at June 30, 2024 | |
| - | | |
$ | - | | |
$ | 885,100 | | |
| 5,087,245,974 | | |
$ | 5,087,246 | | |
$ | 128,488,199 | | |
$ | (91,852,243 | ) | |
$ | 41,723,202 | |
Issuance of common stock upon partial conversion of purchase agreement for cash | |
| - | | |
| - | | |
| - | | |
| 118,513,734 | | |
| 118,514 | | |
| 2,083,411 | | |
| - | | |
| 2,201,925 | |
Stock compensation expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 9,981 | | |
| - | | |
| 9,981 | |
Net Loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (2,046,838 | ) | |
| (2,046,838 | ) |
Balance at September 30, 2024 (unaudited) | |
| - | | |
| - | | |
| 885,100 | | |
| 5,205,759,708 | | |
| 5,205,760 | | |
| 130,581,591 | | |
| (93,899,081 | ) | |
| 41,888,270 | |
Preferred stock converted to common stock | |
| - | | |
| - | | |
| (220,000 | ) | |
| 231,578,947 | | |
| 231,579 | | |
| (11,579 | ) | |
| - | | |
| 220,000 | |
Stock compensation expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 173,516 | | |
| - | | |
| 173,516 | |
Net Loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (3,471,062 | ) | |
| (3,471,062 | ) |
Balance at December 31, 2024 (unaudited) | |
| - | | |
$ | - | | |
$ | 665,100 | | |
| 5,437,338,655 | | |
$ | 5,437,339 | | |
$ | 130,743,528 | | |
$ | (97,370,143 | ) | |
$ | 38,810,724 | |
The accompanying notes are an integral part of these unaudited condensed financial statements.
SUNHYDROGEN, INC.
CONDENSED STATEMENTS
OF CASH FLOWS
(Unaudited)
| |
Six Months Ended December 31, | |
| |
2024 | | |
2023 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | |
| | |
| |
Net Income (Loss) | |
| (5,517,900 | ) | |
| (3,476,819 | ) |
Adjustment to reconcile net income (loss) to net cash (used in) provided by operating activities | |
| | | |
| | |
Depreciation & amortization expense | |
| 19,046 | | |
| 21,780 | |
Stock based compensation expense for services | |
| 183,497 | | |
| 144,963 | |
Loss on redemption of marketable securities | |
| - | | |
| 188,040 | |
Unrealized (gain)/loss on change in fair value of investment, related party | |
| 4,101,402 | | |
| 1,938,835 | |
Change in assets and liabilities : | |
| | | |
| | |
Interest receivable on certificate of deposit | |
| - | | |
| (61,200 | ) |
Prepaid expense | |
| (164,585 | ) | |
| - | |
Accounts payable | |
| (211,335 | ) | |
| 236,392 | |
Accrued expenses | |
| 20,939 | | |
| 59,057 | |
NET CASH USED IN OPERATING ACTIVITIES | |
| (1,568,936 | ) | |
| (948,952 | ) |
| |
| | | |
| | |
CASH FLOWS FROM INVESTING ACTIVITIES | |
| | | |
| | |
Marketable securities purchased | |
| - | | |
| (168,733,113 | ) |
Marketable securities redeemed | |
| - | | |
| 164,145,423 | |
Purchase of certificate of deposit | |
| - | | |
| (5,000,000 | ) |
Purchase of marketable securities unsettled | |
| - | | |
| 4,587,690 | |
Redemption of short term investments in corporate securities | |
| - | | |
| 3,000,000 | |
NET CASH USED IN INVESTING ACTIVITIES | |
| - | | |
| (2,000,000 | ) |
| |
| | | |
| | |
CASH FLOWS FROM FINANCING ACTIVITIES: | |
| | | |
| | |
Repayment of related party note payable | |
| (45,829 | ) | |
| (52,333 | ) |
Net proceeds from common stock purchase agreements | |
| 2,201,925 | | |
| 536,950 | |
NET CASH PROVIDED BY FINANCING ACTIVITIES | |
| 2,156,096 | | |
| 484,617 | |
| |
| | | |
| | |
Net increase (decrease) in cash and cash equivalents | |
| 587,160 | | |
| (2,464,335 | ) |
Cash and cash equivalents - beginning of period | |
| 39,044,795 | | |
| 37,185,989 | |
Cash and cash equivalents - end of period | |
| 39,631,955 | | |
| 34,721,654 | |
| |
| | | |
| | |
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | |
| | | |
| | |
Interest paid | |
$ | 626 | | |
$ | 3,406 | |
Taxes paid | |
$ | - | | |
$ | - | |
| |
| | | |
| | |
SUPPLEMENTAL DISCLOSURES OF NON CASH TRANSACTIONS | |
| | | |
| | |
Conversion of Series C Preferred shares to common stock | |
$ | 220,000.00 | | |
$ | 210,000 | |
The accompanying notes are an integral part of these unaudited condensed financial statements.
SUNHYDROGEN,
INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
AS OF DECEMBER 31, 2024
(Unaudited)
| 1. | ORGANIZATION
AND LINE OF BUSINESS |
Organization
SunHydrogen, Inc. (the “Company”)
was incorporated in the state of Nevada on February 18, 2009. The Company, based in Coralville, IA began operations on February 19, 2009.
Line of Business
The company is currently developing a novel solar-powered
nanoparticle system that mimics photosynthesis to separate hydrogen from water. We intend for technology of this system to be used for
the production of renewable hydrogen to produce renewable electricity and hydrogen for fuel cells and other applications where hydrogen
is used.
SunHydrogen is developing
an efficient and cost-effective way to produce green hydrogen using sunlight and any source of water.
Just like a solar panel is comprised of multiple cells that generate electricity, our hydrogen panel encases multiple hydrogen
generators immersed in water. Each hydrogen generator contains billions of electroplated nanoparticles, autonomously splitting water into
hydrogen and oxygen. We believe our technology has the potential to be one of – if not the most – economical green hydrogen
solutions: Unlike traditional water electrolysis for hydrogen, our process requires no external power other than sunlight and uses efficient
and low-cost materials.
| 2. | SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES |
Basis of Presentation
The accompanying unaudited condensed financial
statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim
financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulations S-X. Accordingly, they do not include all of
the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of
management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the
three and six months ended December 31, 2024 are not necessarily indicative of the results that may be expected for the year ended June
30, 2025. For further information refer to the financial statements and footnotes thereto included in the Company’s Form 10-K for
the year ended June 30, 2024.
Cash and Cash Equivalent
The Company considers all highly liquid investments
with an original maturity of three months or less to be cash equivalents.
The following table provides detail of our cash
and cash equivalents.
| |
December 31,
2024 | | |
June
30,
2024 | |
Cash | |
$ | 29,630,222 | | |
$ | 29,365,997 | |
U.S. Treasury bills | |
| 10,001,733 | | |
| 9,678,798 | |
Total cash and cash equivalents | |
$ | 39,631,955 | | |
$ | 39,044,795 | |
The U.S. Treasury bills have a credit quality
indicator of AA/A.
Concentration risk
Cash includes amounts deposited in financial institutions
in excess of insurable Federal Deposit Insurance Company (FDIC) limits. At times throughout the year, the Company may maintain cash balances
in certain bank accounts in excess of the FDIC limits. As of December 31, 2024, the cash balance in excess of the FDIC limits was $37,834,640.
The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in these accounts.
Use of Estimates
In accordance with accounting
principles generally accepted in the United States, management utilizes estimates and assumptions that affect the reported amounts of
assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates
and assumptions relate to useful lives and impairment of tangible and intangible assets, accruals, income taxes, stock-based compensation
expense, fair value of financial instruments, and other factors. Management believes it has exercised reasonable judgment in deriving
these estimates. Consequently, a change in conditions could affect these estimates.
Property and Equipment
Property and equipment
are stated at cost and are depreciated using straight line over their estimated useful lives.
Computers and peripheral equipment | | | 5 Years | |
Vehicle | | | 5 Years | |
The Company recognized
depreciation expense of $15,706 and $18,411 for the six months ended December 31, 2024 and 2023, respectively.
Intangible Assets
The Company has patent applications to protect
the inventions and processes behind its proprietary bio-based back-sheet, a protective covering for the back of photovoltaic solar modules
traditionally made from petroleum-based film. Intangible assets that have finite useful lives continue to be amortized over their useful
lives.
| | Useful Lives | | December 31, 2024 | | | June 30, 2024 | |
| | | | | | | | |
Trademark-gross | | 10 years | | $ | 1,142 | | | $ | 1,142 | |
Less accumulated amortization | | | | | (885 | ) | | | (827 | ) |
Trademark-net | | | | $ | 257 | | | $ | 315 | |
| | | | | | | | | | |
Patents-gross | | 15 years | | $ | 101,143 | | | $ | 101,143 | |
Less accumulated amortization | | | | | (46,191 | ) | | | (42,909 | ) |
Patents-net | | | | $ | 54,952 | | | $ | 58,234 | |
The Company recognized amortization expense of
$3,340 and $3,369 for the six months ended December 31, 2024 and 2023, respectively.
Future Amortization Expense
Year | |
Amount | |
2025 (remaining) | |
$ | 3,340 | |
2026 | |
| 6,622 | |
2027 | |
| 6,622 | |
2028 | |
| 6,650 | |
2029 | |
| 6,565 | |
Thereafter | |
| 25,410 | |
| |
$ | 55,209 | |
Impairment of Long-lived Assets
The Company applies the provisions of ASC 360,
Property, Plant and Equipment, where applicable to all long-lived assets. ASC 360 addresses accounting and reporting for impairment and
disposal of long-lived assets. The Company periodically evaluates the carrying value of long-lived assets to be held and used in accordance
with ASC 360. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment
are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts.
In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair market value of the long-lived assets.
Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair market values are reduced for the cost
of disposal.
When long-lived assets are sold or retired, the
related cost and accumulated depreciation or amortization are removed from the accounts and any gain or loss is included in the results
of operations. During the six months ended December 31, 2024 and 2023, the Company determined no impairment was required.
Net Earnings (Loss) per Share Calculations
Net earnings (Loss) per share dictates the calculation
of basic earnings (loss) per share and diluted earnings per share. Basic earnings (loss) per share are computed by dividing by the weighted
average number of common shares outstanding during the three and six months ended December 31, 2024 and 2023. Diluted net earnings (loss)
per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock
options and stock-based awards, if dilutive.
The total potential common shares as of December
31, 2024, include 255,465,911 stock options, 78,095,239 common stock purchase warrants, and 700,105,263 common shares issuable upon conversion
of the outstanding 6,651 Series C Preferred shares. Stock options, common stock purchase warrants, and common shares issuable upon conversion
of Series C Preferred shares were not included in the calculation of net earnings per share because their impact on income per share is
antidilutive.
The total potential common shares as of December
31, 2023, include 218,394,499 stock options, 86,495,239 common stock purchase warrants, and 931,684,211 common shares issuable upon conversion
of the outstanding 8,851 Series C Preferred shares. Stock options, common stock purchase warrants, and common shares issuable upon conversion
of Series C Preferred shares were not included in the calculation of net earnings per share because their impact on income per share is
antidilutive.
Stock Based Compensation
The Company accounts for stock option grants issued
and vesting to employees and non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board whereas
the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment
is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based
compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are
no future performance requirements by the non-employee, option grants are immediately vested, and the total stock-based compensation charge
is recorded in the period of the measurement date.
Warrant Accounting
The Company accounts for warrants to purchase
shares of common stock using the estimated fair value on the date of issuance as calculated using the Black-Scholes valuation model.
Fair Value of Financial Instruments
Fair value of financial instruments requires disclosure
of the fair value information, whether or not recognized on the balance sheet, where it is practicable to estimate that value. As of December
31, 2024, the amounts reported for cash, accounts payable and other payables, and accrued expenses approximate the fair value because
of their short maturities.
We adopted ASC Topic 820 for financial instruments
measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance
with accounting principles generally accepted in the United States and expands disclosures about fair value measurements.
Fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and
the lowest priority to unobservable inputs (level 3 measurements).
These tiers include:
|
● |
Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. |
|
● |
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active. |
|
● |
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. |
We measure certain financial instruments at fair
value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows (See Note 7):
December 31, 2024
| |
| Total | | |
| (Level 1) | | |
| (Level 2) | | |
| (Level 3) | |
Assets: | |
| | | |
| | | |
| | | |
| | |
Equity securities, related party | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
| |
$ | - | | |
$ | - | | |
$ | - | | |
$ | - | |
June 30, 2024
| |
Total | | |
(Level 1) | | |
(Level 2) | | |
(Level 3) | |
Assets: | |
| | |
| | |
| | |
| |
Equity securities, related party | |
$ | 4,101,402 | | |
$ | - | | |
$ | 4,101,402 | | |
$ | - | |
| |
$ | 4,101,402 | | |
$ | - | | |
$ | 4,101,402 | | |
$ | - | |
As of December 31, 2024, the Equity securities, related party had a
fair value of $0 which was measured using a level 3 input due to the underlying securities no longer trading on an active stock exchange
(See Note 7).
Research and Development
Research and development costs are expensed as
incurred. Total research and development costs were $1,234,323 and $1,195,327 for the six months ended December 31, 2024 and 2023,
respectively.
Advertising and Marketing
Advertising and marketing cost are expensed as
incurred. Total advertising and marketing costs were $647 and $44,000 for the six months ended December 31, 2024 and 2023, respectively.
Accounting for Derivatives
The Company evaluates all of its financial instruments
to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments
that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each
reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments,
the Company uses a probability weighted average series Binomial lattice formula pricing models to value the derivative instruments at
inception and on subsequent valuation dates.
The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative
instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the
derivative instrument could be required within 12 months of the balance sheet date.
Recently Issued Accounting Pronouncements
Management believes that no recently issued accounting
standards, which are not yet effective, would have a material impact on the accompanying unaudited financial statements as of December
31, 2024, if adopted at this time.
Reclassification
Certain accounts from prior periods have been reclassified to conform
to the current period presentation.
Series C Preferred Stock
On December 15, 2021, the Company filed a certificate
of designation of Series C Preferred Stock with the Secretary of State of Nevada, designating 17,000 shares of preferred stock as Series
C Preferred Stock. Each share of Series C Preferred Stock has a stated value of $100 and is convertible into shares of common stock of
the Company at a conversion price of $0.00095. The Series C Preferred Stock holders are entitled to receive out of any funds and assets
of the Company legally available prior and in preference to any declaration or payment of any dividend on the common stock of the Company,
cumulative dividends, at an annual rate of 10% of the stated value, payable in cash or shares of common stock. In the event the Company
declares or pays a dividend on its shares of common stock (other than dividend payable in shares of common stock), the holders of Series
C Preferred Stock will also be entitled to receive payment of such dividend on an as--converted basis. The Series C Preferred Stock confers
no voting rights on holders, except with respect to matters that materially and adversely affect the voting powers, rights or preferences
of the Series C Preferred Stock or as otherwise required by applicable law. Upon liquidation, dissolution and winding up of the Company,
the holders of Series C Preferred Stock will be entitled to receive, before any payments will made or any assets distributed to the holders
of the common stock, the stated value of the Series C Preferred Shares plus any declared but unpaid dividends. No other current or future
equity holders of the Company will have higher priority of liquidation preference than holders of Series C Preferred Stock.
The Series C Preferred Stock is presented as mezzanine
equity because it is redeemable at a fixed or determinable amount upon an event that is outside of the Company’s control.
During the six months ended December 31, 2024,
an investor converted 2,200 preferred shares with a stated value of $220,000, at a conversion price of $0.00095, into 231,578,947 common
shares. No gain or loss was recognized in the financial statements.
During the six months ended December 31, 2023,
an investor converted 2,100 preferred shares with a stated value of $210,000, at a conversion price of $0.00095, into 221,052,632 common
shares. No gain or loss was recognized in the financial statements.
As of December 31, 2024 and June 30, 2024, the
Company had 6,651 and 8,851 shares of Series C Preferred Stock outstanding, respectively. The fair value of the outstanding shares was
$665,100 and $885,100, respectively.
Six Months Ended December 31, 2024
On November 11, 2022, the Company entered into
a Purchase Agreement with an investor for the sale of up to $45,000,000 of shares of common stock. For the six months ended December
31, 2024, the Company issued 118,513,734 shares of common stock for $2,250,000 under the purchase agreement at prices of
$0.0156 - $0.02024, pursuant to purchase notices received from the investor. The finance cost of $48,075 was deducted from the
gross proceeds received, leaving net proceeds of $2,201,925.
On November 22, 2024, the Company issued 231,578,947
shares of common stock, upon conversion of 2,200 shares of preferred stock with a stated value of $220,000 at a conversion price of $0.00095.
Six Months Ended December 31, 2023
On November 11, 2022, the Company entered into
a Purchase Agreement with an investor for the sale of up to $45,000,000 of common stock. For the six months ended December 31, 2023, the
Company issued 50,463,718 shares of common stock for $550,000 under the purchase agreement at prices of $0.0094 - $0.0134, pursuant to
purchase notices received from the investor. The finance cost of $13,050 was deducted from the gross proceeds received, leaving gross
proceeds of $536,950.
On September 8, 2023, the Company issued 221,052,632
shares of common stock, upon conversion of 2,100 shares of preferred stock with a stated value of $210,000 at a conversion price of $0.00095.
2019 Equity Stock Incentive Plan
On December 17, 2018, the Board of Directors approved
and adopted the 2019 Equity Incentive Plan (“the 2019 Plan”), with 300,000,000 shares reserved for issuance. The purpose of
the 2019 Plan is to promote the success of the Company and to increase stockholder value by providing an additional means through the
grant of awards to attract, motivate, retain, and reward selected employees and other eligible persons. The awards are performance-based
compensation that are granted under the 2019 Plan as incentive stock options (ISO) or nonqualified stock options. The per share exercise
price for each option shall not be less than 100% of the fair market value of a share of common stock on the date of grant of the option.
The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions for services
and for financing cost.
As of December 31, 2024, under the 2019 Equity
Incentive Plan, there were 285,270,561 stock options and shares issued, with 14,729,439 shares remaining available for issuance.
2022 Equity Stock Incentive Plan
On January 27, 2022, the Company adopted the 2022
Equity Incentive Plan, to enable the Company to attract and retain the types of employees, consultants, and directors who will contribute
to the Company’s long-range success. The maximum number of shares of common stock that may be issued under the 2022 Plan is initially
400,000,000. The number of shares will automatically be increased on the first day of the Company’s fiscal year beginning in 2023
so that the total number of shares issuable equals fifteen percent (15%) of the Company’s fully diluted capitalization on the first
day of the Company’s fiscal year, unless the Board adopts a resolution providing that the number of shares issuable under the 2022
Plan shall not be so increased.
As of July 1, 2024, the maximum number of shares
issuable under the 2022 Equity Incentive Plan was increased to 953,548,700 shares, based on the Company’s fully diluted capitalization
of 6,356,991,335. As of December 31, 2024, there were 448,600,000 stock options and shares issued, with 504,948,700 shares remaining available
for issuance.
| 6. | STOCK OPTIONS AND WARRANTS |
Options
Transactions involving our options are summarized
as follows:
| |
| | |
| | |
Weighted | |
| |
| | |
Weighted | | |
Average | |
| |
| | |
Average | | |
Grant-Date | |
| |
Number of | | |
Exercise | | |
Per Share | |
| |
Options | | |
Price | | |
Fair Value | |
Options outstanding at June 30, 2024 | |
| 266,894,499 | | |
$ | 0.011 | | |
$ | 0.011 | |
Granted | |
| 275,000,000 | | |
$ | 0.017 | | |
$ | 0.013 | |
Canceled/Expired | |
| (6,928,588 | ) | |
$ | 0.010 | | |
$ | 0.010 | |
Exercised | |
| - | | |
$ | - | | |
$ | - | |
Options outstanding at December 31, 2024 | |
| 534,965,911 | | |
$ | 0.0139 | | |
$ | 0.012 | |
Details of our options outstanding as of December
31, 2024, is as follows:
Options Exercisable | | | Weighted Average Exercise Price of Options Exercisable | | | Weighted Average Contractual Life of Options Exercisable
(Years) | | | Weighted Average Contractual Life of Options Outstanding (Years) | |
| 255,465,911 | | | | 0.011 | | | | 2.15 | | | | 4.85 | |
Total stock compensation expense related to the
options for the six months ended December, 2024 and 2023, was $183,497 and $144,963, respectively. As of December 31, 2024 there was approximately
$3.5 million of unrecognized compensation cost related to the Options, which is expected to be recognized over a remaining weighted-average
vesting period of approximately 1.41 years.
Warrants
Transactions involving our warrants are summarized
as follows:
| |
| | |
Weighted | |
| |
Number of
Shares | | |
Average
Exercise Price | |
Warrants outstanding at June 30, 2024 | |
| 78,095,239 | | |
$ | 0.121 | |
Issued | |
| - | | |
$ | - | |
Canceled/Expired | |
| - | | |
$ | - | |
Exercised | |
| - | | |
$ | - | |
Warrants outstanding at December 31, 2024 | |
| 78,095,239 | | |
$ | 0.121 | |
Details of our warrants outstanding as of December
31, 2024, is as follows:
Warrants Exercisable | | | Weighted Average Contractual Life of Warrants Outstanding and Exercisable (Years) | |
| 78,095,239 | | | | 1.17 | |
7. EQUITY SECURITIES, RELATED PARTY
On November 11, 2022, the Company entered into
a subscription agreement with TECO 2030 ASA (“TECO”). TECO was a Norwegian based clean tech company developing zero-emission
technology for the maritime and heavy industry. They were developing PEM hydrogen fuel cell stacks and PEM hydrogen fuel cell modules,
that enable ships and other heavy-duty applications to become emissions-free. TECO was listed on Euronext Growth on Oslo Stock Exchange
under the ticker TECO. Pursuant to the subscription agreement, the Company purchased 13,443,875 shares of TECO stock for an aggregate
consideration of $7 million in USD, at an exchange rate of NOK 10.4094. The shares purchased are adjusted to fair value based on unrealized
gain or loss at the end of each period. At the time of this transaction, the Company and TECO became related parties due to the Company
owning an 8.3% interest in TECO. Subsequent to the equity purchase, Timothy Young, CEO of the Company, was elected to the board of TECO
in January of 2023.
Also, on November 11, 2022 the Company purchased
a bond receivable of TECO for a subscription amount of $3 million. The issuance of the bond receivable was through a Tap Issue Addendum
to TECO’s secured convertible notes agreement dated June 1, 2022, pursuant to which Nordic Trustee AS was acting as the security
agent on behalf of the note holders. The bond receivable would have matured on June 1, 2025, and would have been converted into shares
at a rate of NOK 5.0868 per share. The note bore interest at the rate of 8% per annum, which was paid quarterly in arrears. For the six
months ended December 31, 2023, the Company recognized interest income of $114,652.
In April of 2024, all investors of TECO bonds
received an option to convert their bonds to receive one share for every two NOK. On May 24, 2024 the Company agreed to the terms and
conversion, and agreed to receive 15,884,744 shares of TECO stock in exchange for the convertible bond receivable of $3,000,000 and unpaid
interest. The bond receivable had a principal amount of NOK 31,228,200, and accrued and unpaid interest up to May 24, 2024 of NOK 541,289,
for a total of NOK 31,769,489. The value of the shares converted on May 24, 2024 was $3,139,302 with contributed capital gain on conversion
of convertible bond of $85,815 and interest received of $53,487.
On September 10, 2024, after a delay to allow
time for legal review and clarification of the investment statements, the bond was returned. Upon receipt of the 15,884,744 shares, the
Company owned a total of 29,328,619 shares, which as of September 30, 2024 represented approximately 13.29% of the outstanding shares of
TECO.
The CEO of the Company elected to not seek reelection
to the board of directors at the annual general meeting in June and is no longer a director of TECO after June 19, 2024. The CEO of the
Company never received compensation of any kind for his role as director from January of 2023 through June 19, 2024.
During December 2024, it came to the Company’s
attention that TECO filed for bankruptcy and their shares were suspended from trading on the Euronext Growth on Oslo Stock Exchange. In
January 2025, TECO was delisted. Based on these events, the Company determined the fair value of their shares was $0 as of December 31,
2024.
On December 17, 2024, the Company entered a
share allocation agreement with TECO HOLDING AS, in which Bacchus AS (“Newco” and a wholly owned subsidiary of TECO
HOLDINGS AS) intends to acquire the shares and other assets owned by TECO 2030 ASA. TECO HOLDINGS AS then agreed to transfer shares
in Newco equal to 13.32% of the total shares of Newco to the Company free of charge, encumbrances, and other liens. Concurrently
with the transfer of shares under the allocation agreement, a representative of the Company shall, whenever preferred, be appointed
to the board of directors of Newco. As of December 31, 2024, due to Newco recently being formed and there being no readily determinable
fair value, the Company determined the fair value of the Newco shares was $0.
The following table summarizes our equity investments
in TECO:
Date of Investment | |
Number of
Shares | | |
Cost Basis | | |
Fair Value
as of
June 30,
2024 | | |
Unrealized Loss | | |
Fair Value
as of
December 31,
2024 | |
November 24, 2022 | |
| 13,443,875 | | |
$ | 7,000,000 | | |
$ | 1,880,032 | | |
$ | (1,880,032 | ) | |
$ | - | |
May 24, 2024 | |
| 15,884,744 | | |
| 3,139,302 | | |
| 2,221,370 | | |
| (2,221,370 | ) | |
| - | |
Total | |
| 29,328,619 | | |
$ | 10,139,302 | | |
$ | 4,101,402 | | |
$ | (4,101,402 | ) | |
$ | - | |
The following table summarizes our investment
income.
| |
December 31,
2024 | | |
December 31,
2023 | |
Interest earned on cash (NOTE 2) | |
$ | 675,207 | | |
$ | 52,468 | |
Interest earned on Treasury Bills (NOTE 2) | |
| 240,475 | | |
| 664,157 | |
Interest earned on Certificates of Deposit (NOTE 9) | |
| - | | |
| 61,200 | |
Interest earned on Corporate Bonds | |
| - | | |
| 54,375 | |
Interest earned on TECO bond (NOTE 7) | |
| - | | |
| 114,652 | |
Dividends and other | |
| 3,686 | | |
| 13,741 | |
Total investment income | |
$ | 919,368 | | |
$ | 960,593 | |
On September 12, 2023, the Company invested in
a $5,000,000 certificate of deposit (CD), which matured on March 12, 2024. CDs should be reported as part of cash and cash equivalents
at cost plus accrued interest if less than 90 days from the purchase date, and on its own line in the financial statements if the purchase
is greater than 90 days. The CD has been classified as a short-term investment due to the length of time to maturity at acquisition and
was measured using Level 2. The CD was reinvested upon maturity. The Company recognized interest income of $61,200 which was reported in
the Company’s financial statements as of December 31, 2023.
| 10. | COMMITMENTS AND CONTINGENCIES |
Effective October 1, 2024, the Company extended
its research agreement with the University of Iowa through September 30, 2025. As consideration under the research agreement, the University
of Iowa will receive a maximum of $302,459 from the Company in four equal installments of $75,615. The agreement can be terminated
by either party upon sixty (60) days prior written notice to the other. As of December 31, 2024, there is a balance due of $75,615 per
the agreement.
Effective October 1, 2024, the Company extended
its research agreement with the University of Michigan through September 30, 2025. As consideration under the research agreement, the
University of Michigan will receive a maximum of $252,246 from the Company. In the event of early termination by the Sponsor, the Sponsor
will pay all costs accrued by the University as of the date of termination, including non-cancellable obligations. As of December 31,
2024, there is a balance due of $63,062 per the agreement and $40,091 per the prior amended research agreement for a total of $103,153.
The Company began renting lab space in February
2022. The lab rental is on a month-to-month basis and is cancellable with a thirty (30) day notice. On April 1, 2024, the Company renewed
the space needed for its lab work at a monthly rent of $6,400 per month. Due to the rental being month-to-month, ASC 842 lease accounting
is not applicable.
In the normal course of business, the Company
may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject
to many uncertainties, and outcomes are not predictable with assurance. In the opinion of management, the ultimate
disposition of these matters will not have a material adverse effect on the Company’s financial position or
results of operation.
Shareholders Loan
During the period ended December 31, 2022, the
Company entered into a $211,750 loan with the Company’s CEO for the repayment of accrued salary expense. The loan bore interest
of five percent (5%) and was to be repaid with monthly payments of $9,290, including interest and principal over a two-year period. As
of December 31, 2024 and June 30, 2024, the principal balance remaining on the loan was $0 and $45,829, respectively and interest paid
during the six months ended December 31, 2024 and 2023 was $620 and $3,405, respectively.
Other Related Party Activity
See Note 7 for related party transactions with
respect to TECO 2030 A.S.A. and Newco.
Management evaluated subsequent events as of the
date of the financial statements pursuant to ASC TOPIC 855 and had the following subsequent events to report.
Item 2. Management’s Discussion and Analysis
of Financial Condition and Results of Operations.
Cautionary Statement Regarding Forward-Looking
Statements
The information in this
report may contain forward-looking statements. These forward-looking statements involve risks and uncertainties, including statements
regarding our capital needs, business strategy and expectations. Any statements that are not of historical fact may be deemed to be forward-looking
statements. These forward-looking statements involve substantial risks and uncertainties. In some cases you can identify forward-looking
statements by terminology such as “may,” “will,” “should,” “expect,” “plan,”
“intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,”
or “continue”, the negative of the terms or other comparable terminology. Actual events or results may differ materially from
the anticipated results or other expectations expressed in the forward-looking statements. In evaluating these statements, you should
consider various factors, including the risks included from time to time in our reports filed with the Securities and Exchange Commission,
or the SEC. These factors may cause our actual results to differ materially from any forward-looking statements. We disclaim any obligation
to publicly update these statements, or disclose any difference between actual results and those reflected in these statements, except
as may be required under applicable law.
Unless the context otherwise
requires, references in this Form 10-Q to “we,” “us,” “our,” “SunHydrogen” or the “Company”
refer to SunHydrogen, Inc.
Overview
At
SunHydrogen, our goal is to replace fossil fuels with clean, renewable hydrogen.
Hydrogen
is the most abundant chemical element in the universe. When hydrogen fuel is used to power transportation and industry, the only byproduct
left behind is pure water, unlike hydrocarbon fuels such as oil, coal and natural gas that emit carbon dioxide and other harmful pollutants
into the atmosphere. However, naturally occurring elemental hydrogen is rare - so rare, in fact, that today about 95% of hydrogen is produced
from steam reforming of natural gas (Source: US Department of Energy, Hydrogen Fuel Basics). This process is both economically
and environmentally unsound.
The
SunHydrogen solution offers an efficient and cost-effective way to produce truly green hydrogen using sunlight and any source of water.
Our core technology is a self-contained, nanoparticle-based hydrogen generator that mimics photosynthesis to split water molecules, resulting
in hydrogen. By optimizing the science of water electrolysis at the nano-level, we believe we have developed a low-cost method to potentially
produce environmentally friendly renewable hydrogen.
We
believe renewable hydrogen has already proven itself to be a key solution in helping the world meet climate targets, and we believe our
technology potentially offers solutions to the challenges that the hydrogen future presents, including cost of production and transportation.
Because
our process only requires sunlight and water, our technology can be installed near the point of hydrogen use. This eliminates the need
for pipelines and trucks that result in high carbon emissions and high capital investment. Additionally, because our process directly
uses the electrical charges created by sunlight to generate hydrogen, our nanoparticle technology does not rely on grid power or require
the costly power electronics that conventional electrolyzers do. Lastly, our planned scalable system configuration of many individual
hydrogen-generating panels ensures redundancy, security and stability.
With
a target cost of $2.50/kg., we aspire for our technology to be cost-competitive with brown hydrogen and below the cost of clean hydrogen
competitors. We believe our solution has the potential to clear a path for green hydrogen to compete with natural gas hydrogen and gain
mass market acceptance as a true replacement for fossil fuels.
Our
technology is primarily developed at three laboratories - our independent laboratory in Coralville, Iowa, the SunHydrogen laboratory at
the University of Iowa, and the Singh laboratory at University of Michigan.
Additionally,
in parallel to the ongoing development of our own technology, we may begin pursuing synergistic strategic investments in the hydrogen
space. SunHydrogen is committed to furthering renewable hydrogen technology to grow the hydrogen ecosystem, and we are actively pursuing
opportunities for investment and acquisition of complimentary hydrogen technologies.
Critical Accounting Policies
Our
discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been
prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial
statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses,
and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related
to impairment of property, plant and equipment, intangible assets, deferred tax assets and fair value computation using the Binomial valuation
option pricing model. We base our estimates on historical experience and on various other assumptions, such as the trading value of our
common stock and estimated future undiscounted cash flows, that we believe to be reasonable under the circumstances, the results of which
form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources.
Actual results may differ from these estimates under different assumptions or conditions; however, we believe that our estimates, including
those for the above-described items, are reasonable.
Use of Estimates
In
accordance with accounting principles generally accepted in the United States, management utilizes estimates and assumptions that affect
the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements
as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
These estimates and assumptions relate to useful lives and impairment of tangible and intangible assets, accruals, income taxes, stock-based
compensation expense, Binomial lattice valuation model inputs, derivative liabilities and other factors. Management believes it has exercised
reasonable judgment in deriving these estimates. Consequently, a change in conditions could affect these estimates.
Fair Value of Financial
Instruments
Fair
value of financial instruments requires disclosure of the fair value information, whether or not recognized in the balance sheet, where
it is practicable to estimate that value. As of December 31, 2024, the amounts reported for cash, investment in affiliate, accrued interest
and other expenses, notes payables, and derivative liability approximate the fair value because of their short maturities.
We
adopted ASC Topic 820 for financial instruments measured as fair value on a recurring basis. ASC Topic 820 defines fair value, established
a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures
about fair value measurements.
Recently Issued Accounting
Pronouncements
Management
reviewed currently issued pronouncements during the six months ended December 31, 2024, and does not believe that any recently issued,
but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial
statements. Pronouncements are disclosed in notes to the financial statements.
Results of Operations for the Three Months
ended December 31, 2024 compared to Three Months Ended December 31, 2023
Operating Expenses
Operating
expenses for the three months ended December 31, 2024 were $1,257,942, compared to $1,264,882 for the three months ended December 31,
2023. The net change of $6,940 in operating expenses consisted primarily of increases in general and administrative expenses offset by
decreases in research and development costs.
Other Income/(Expenses)
Other
income and (expenses) for the three months ended December 31, 2024 were $(2,213,120), compared to $(1,763,825) for the three months ended
December 31, 2023. The decrease in other income of $449,295 was the result of a larger unrealized loss on the Company’s investment
in TECO (Equity securities, related party on the Condensed Balance Sheets) in the current period compared to in the prior year and a decrease
in investment income in the current period compared to the prior year.
Net Loss
For
the three months ended December 31, 2024, our net loss was $3,471,062, compared to a net loss of $3,028,707 for the three months ended
December 31, 2023. The increase in net loss of $442,355 was primarily due to an increase in the unrealized loss on the Company’s
investment in TECO (Equity securities, related party on the Condensed Balance Sheets) in the current period compared to the prior year.
These equity securities are measured at fair value on a recurring basis. In addition, the Company has not generated any revenues.
Results of Operations for the Six Months ended
December 31, 2024 compared to Six Months Ended December 31, 2023
Operating Expenses
Operating
expenses for the six months ended December 31, 2024 were $2,294,369, compared to $2,263,612 for the six months ended December 31, 2023.
The net change of $30,757 in operating expenses consisted primarily of an increase in research and development costs and general and administrative
expenses partially offset by decreases in selling and marketing expenses.
Other Income/(Expenses)
Other
income and (expenses) for the six months ended December 31, 2024 were $(3,223,531), compared to $(1,213,207) for the six months ended
December 31, 2023. The decrease in other income of $2,010,324 was primarily the result of a larger unrealized loss on the Company’s
investment in TECO (Equity securities, related party on the Condensed Balance Sheets) in the current period compared to the prior year
partially offset by a realized loss on redemption of marketable securities in the prior year with no similar transactions in the current
year.
Net Loss
For
the six months ended December 31, 2024, our net loss was $5,517,900, compared to a net loss of $3,476,819 for the six months ended December
31, 2023. The increase in net loss of $2,041,081 was primarily due to an increase in the unrealized loss on the Company’s investment
in TECO (Equity securities, related party on the Condensed Balance Sheets) in the current period compared to the prior year. These equity
securities are measured at fair value on a recurring basis. In addition, the Company has not generated any revenues.
Liquidity and Capital Resources
Liquidity is the ability of
a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing
basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts
payable and capital expenditures.
As of December 31, 2024, we
had working capital of $39,273,251, compared to $42,386,683 as of June 30, 2024. This decrease in working capital of $3,113,432 was primarily
due to a decrease in equity securities, related party.
Cash used in operating activities
was $1,568,936 for the six months ended December 31, 2024, compared to $948,952 for the six months ended December 31, 2023. The net increase
of $619,984 in cash used in operating activities was due to increases in the net loss, prepaid expenses, accounts payable, and decrease
in loss on redemption of marketable securities offset by an increase in unrealized loss in equity securities, related party. The Company
has had no revenues.
Cash used in investing activities
during the six months ended December 31, 2024 and December 31, 2023 was $0 and $2,000,000, respectively. The net decrease of $2,000,000
in cash used in investing activities was due to the purchase of certificate of deposits offset by the redemption of short-term investments
in corporate securities during the six months ended December 31, 2023 with no similar transactions in the six months ended December 31,
2024.
Cash provided by financing
activities during the six months ended December 31, 2024 and December 31, 2023 was $2,156,096 and $484,617, respectively. The net increase
of $1,671,479 in cash provided by financing activities was due to increased proceeds from a Purchase Agreement entered with an investor
for the sale of up to $45,000,000 of common stock.
Our
ability to continue as a going concern is dependent upon raising capital through financing transactions and future revenue. Our capital
needs have primarily been met from the proceeds of private placements and registered offerings of our securities, as we have not generated
any revenues to date.
We
have historically obtained funding from investors, through private placements and registered offerings of equity and debt securities.
Management believes that the Company will be able to continue to raise funds through the sale of its securities to its existing shareholders
and prospective new investors, which will provide the additional cash needed to meet the Company’s obligations as they become due
and will allow the Company to continue to develop its core business. There can be no assurance that we will be able to continue raising
the required capital for our operations on terms and conditions that are acceptable to us, or at all. If we are unable to obtain sufficient
funds, we may be forced to curtail and/or cease our operation.
Off-Balance Sheet Arrangements
We do not have any off-balance
sheet arrangements that are reasonably likely to have a current or future effect on our financial condition, revenues or expenses, result
of operations, liquidity or capital expenditures.
Item 3. Quantitative and Qualitative Disclosures
About Market Risk.
Not required for smaller reporting
companies.
Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our
CEO and our Acting CFO, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e)
of the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our CEO and our Acting CFO concluded
that, due to the material weakness described below, our disclosure controls and procedures as of the end of the period covered by this
report were not effective to ensure that information required to be disclosed is made known to management and others, as appropriate,
to allow timely decision regarding required disclosure and that the information required to be disclosed by us in reports that we file
or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Commission’s
rules and forms and (ii) accumulated and communicated to our management, including our CEO and Acting CFO, or persons performing similar
functions, as appropriate to allow timely decisions regarding required disclosure.
Our management, including our principal executive
officer and acting principal financial officer, does not expect that our disclosure controls and procedures or our internal controls will
prevent all error or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance
that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource
constraints, and the benefits of controls must be considered relative to their costs. Due to the inherent limitations in all control systems,
no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. To
address the material weaknesses, we performed additional analysis and other post-closing procedures in an effort to ensure our financial
statements included in this report have been prepared in accordance with generally accepted accounting principles. Accordingly, management
believes that the financial statements included in this report fairly present in all material respects our financial condition, results
of operations and cash flows for the periods presented.
As of December 31, 2024, due
to the inherent issue of segregation of duties in a small company, we have relied heavily on entity or management review controls and
engaged an outside financial consultant to lessen the issue of segregation of duties over accounting, financial close procedures and controls
over financial statement disclosure. Accordingly, management has determined that this control deficiency constitutes a material weakness.
Changes in Internal Control Over Financial
Reporting
There was no change to our
internal control over financial reporting that occurred during our fiscal quarter ended December 31, 2024 that has materially affected,
or is reasonably likely to materially affect, our internal control over financial reporting.
PART II - OTHER INFORMATION
Item 1. Legal Proceedings.
We are not currently a party
to, nor is any of our property currently the subject of, any material legal proceeding.
Item 1A. Risk Factors.
There are no material changes
from the risk factors previously disclosed in our annual report on Form 10-K filed with the SEC on September 30, 2024.
Item 2. Unregistered Sales of Equity Securities
and Use of Proceeds.
None.
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
Not applicable.
Item 5. Other Information.
During the quarter ended December
31, 2024, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule
10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
Item 6. Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
February 10, 2025 |
SUNHYDROGEN, INC. |
|
|
|
|
By: |
/s/ Timothy Young |
|
|
Timothy Young |
|
|
Chief Executive Officer and |
|
|
Acting Chief Financial Officer |
|
|
(Principal Executive Officer, |
|
|
Principal Financial Officer and |
|
|
Principal Accounting Officer) |
0001481028
false
2025
Q2
--06-30
0001481028
2024-07-01
2024-12-31
0001481028
2025-02-10
0001481028
2024-12-31
0001481028
2024-06-30
0001481028
us-gaap:RelatedPartyMember
2024-12-31
0001481028
us-gaap:RelatedPartyMember
2024-06-30
0001481028
us-gaap:TrademarksMember
2024-12-31
0001481028
us-gaap:TrademarksMember
2024-06-30
0001481028
us-gaap:TradeSecretsMember
2024-12-31
0001481028
us-gaap:TradeSecretsMember
2024-06-30
0001481028
us-gaap:SeriesCPreferredStockMember
2024-12-31
0001481028
us-gaap:SeriesCPreferredStockMember
2024-06-30
0001481028
2024-10-01
2024-12-31
0001481028
2023-10-01
2023-12-31
0001481028
2023-07-01
2023-12-31
0001481028
us-gaap:PreferredStockMember
2023-06-30
0001481028
hysr:MezzanineMember
2023-06-30
0001481028
us-gaap:CommonStockMember
2023-06-30
0001481028
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0001481028
us-gaap:RetainedEarningsMember
2023-06-30
0001481028
2023-06-30
0001481028
us-gaap:PreferredStockMember
2023-07-01
2023-09-30
0001481028
hysr:MezzanineMember
2023-07-01
2023-09-30
0001481028
us-gaap:CommonStockMember
2023-07-01
2023-09-30
0001481028
us-gaap:AdditionalPaidInCapitalMember
2023-07-01
2023-09-30
0001481028
us-gaap:RetainedEarningsMember
2023-07-01
2023-09-30
0001481028
2023-07-01
2023-09-30
0001481028
us-gaap:PreferredStockMember
2023-09-30
0001481028
hysr:MezzanineMember
2023-09-30
0001481028
us-gaap:CommonStockMember
2023-09-30
0001481028
us-gaap:AdditionalPaidInCapitalMember
2023-09-30
0001481028
us-gaap:RetainedEarningsMember
2023-09-30
0001481028
2023-09-30
0001481028
us-gaap:PreferredStockMember
2023-10-01
2023-12-31
0001481028
us-gaap:CommonStockMember
2023-10-01
2023-12-31
0001481028
us-gaap:AdditionalPaidInCapitalMember
2023-10-01
2023-12-31
0001481028
us-gaap:RetainedEarningsMember
2023-10-01
2023-12-31
0001481028
hysr:MezzanineMember
2023-10-01
2023-12-31
0001481028
us-gaap:PreferredStockMember
2023-12-31
0001481028
hysr:MezzanineMember
2023-12-31
0001481028
us-gaap:CommonStockMember
2023-12-31
0001481028
us-gaap:AdditionalPaidInCapitalMember
2023-12-31
0001481028
us-gaap:RetainedEarningsMember
2023-12-31
0001481028
2023-12-31
0001481028
us-gaap:PreferredStockMember
2024-06-30
0001481028
hysr:MezzanineMember
2024-06-30
0001481028
us-gaap:CommonStockMember
2024-06-30
0001481028
us-gaap:AdditionalPaidInCapitalMember
2024-06-30
0001481028
us-gaap:RetainedEarningsMember
2024-06-30
0001481028
us-gaap:PreferredStockMember
2024-07-01
2024-09-30
0001481028
hysr:MezzanineMember
2024-07-01
2024-09-30
0001481028
us-gaap:CommonStockMember
2024-07-01
2024-09-30
0001481028
us-gaap:AdditionalPaidInCapitalMember
2024-07-01
2024-09-30
0001481028
us-gaap:RetainedEarningsMember
2024-07-01
2024-09-30
0001481028
2024-07-01
2024-09-30
0001481028
us-gaap:PreferredStockMember
2024-09-30
0001481028
hysr:MezzanineMember
2024-09-30
0001481028
us-gaap:CommonStockMember
2024-09-30
0001481028
us-gaap:AdditionalPaidInCapitalMember
2024-09-30
0001481028
us-gaap:RetainedEarningsMember
2024-09-30
0001481028
2024-09-30
0001481028
us-gaap:PreferredStockMember
2024-10-01
2024-12-31
0001481028
hysr:MezzanineMember
2024-10-01
2024-12-31
0001481028
us-gaap:CommonStockMember
2024-10-01
2024-12-31
0001481028
us-gaap:AdditionalPaidInCapitalMember
2024-10-01
2024-12-31
0001481028
us-gaap:RetainedEarningsMember
2024-10-01
2024-12-31
0001481028
us-gaap:PreferredStockMember
2024-12-31
0001481028
hysr:MezzanineMember
2024-12-31
0001481028
us-gaap:CommonStockMember
2024-12-31
0001481028
us-gaap:AdditionalPaidInCapitalMember
2024-12-31
0001481028
us-gaap:RetainedEarningsMember
2024-12-31
0001481028
hysr:StockOptionsMember
2024-07-01
2024-12-31
0001481028
hysr:CommonStockPurchaseWarrantsMember
2024-07-01
2024-12-31
0001481028
us-gaap:CommonStockMember
2024-07-01
2024-12-31
0001481028
us-gaap:SeriesCPreferredStockMember
2024-07-01
2024-12-31
0001481028
hysr:StockOptionsMember
2023-07-01
2023-12-31
0001481028
hysr:CommonStockPurchaseWarrantsMember
2023-07-01
2023-12-31
0001481028
us-gaap:CommonStockMember
2023-07-01
2023-12-31
0001481028
us-gaap:SeriesCPreferredStockMember
2023-07-01
2023-12-31
0001481028
us-gaap:FairValueInputsLevel3Member
us-gaap:RelatedPartyMember
2024-12-31
0001481028
us-gaap:CashMember
2024-12-31
0001481028
us-gaap:CashMember
2024-06-30
0001481028
us-gaap:USTreasuryBillSecuritiesMember
2024-12-31
0001481028
us-gaap:USTreasuryBillSecuritiesMember
2024-06-30
0001481028
us-gaap:ComputerEquipmentMember
2024-12-31
0001481028
us-gaap:VehiclesMember
2024-12-31
0001481028
us-gaap:TrademarksMember
2024-12-31
0001481028
us-gaap:TrademarksMember
2024-06-30
0001481028
us-gaap:PatentsMember
2024-12-31
0001481028
us-gaap:PatentsMember
2024-06-30
0001481028
us-gaap:FairValueInputsLevel1Member
2024-12-31
0001481028
us-gaap:FairValueInputsLevel2Member
2024-12-31
0001481028
us-gaap:FairValueInputsLevel3Member
2024-12-31
0001481028
us-gaap:FairValueInputsLevel1Member
2024-06-30
0001481028
us-gaap:FairValueInputsLevel2Member
2024-06-30
0001481028
us-gaap:FairValueInputsLevel3Member
2024-06-30
0001481028
us-gaap:SeriesCPreferredStockMember
2021-12-15
0001481028
us-gaap:SeriesCPreferredStockMember
2021-12-15
2021-12-15
0001481028
us-gaap:PreferredStockMember
2024-07-01
2024-12-31
0001481028
us-gaap:SeriesCPreferredStockMember
2023-07-01
2023-12-31
0001481028
hysr:PurchaseAgreementMember
us-gaap:CommonStockMember
2022-11-11
2022-11-11
0001481028
us-gaap:CommonStockMember
2024-07-01
2024-12-31
0001481028
srt:MinimumMember
us-gaap:CommonStockMember
2024-07-01
2024-12-31
0001481028
srt:MaximumMember
us-gaap:CommonStockMember
2024-07-01
2024-12-31
0001481028
hysr:PurchaseAgreementMember
2024-12-31
0001481028
us-gaap:CommonStockMember
2024-11-22
2024-11-22
0001481028
us-gaap:PreferredStockMember
2024-11-22
2024-11-22
0001481028
us-gaap:PreferredStockMember
2024-11-22
0001481028
us-gaap:CommonStockMember
2022-11-11
2022-11-11
0001481028
us-gaap:CommonStockMember
hysr:PurchaseAgreementWithAnInvestorMember
2023-07-01
2023-12-31
0001481028
srt:MinimumMember
hysr:PurchaseAgreementWithAnInvestorMember
2023-12-31
0001481028
srt:MaximumMember
hysr:PurchaseAgreementWithAnInvestorMember
2023-12-31
0001481028
hysr:PurchaseAgreementWithAnInvestorMember
2023-07-01
2023-12-31
0001481028
us-gaap:CommonStockMember
2023-09-08
2023-09-08
0001481028
us-gaap:PreferredStockMember
2023-09-08
2023-09-08
0001481028
us-gaap:PreferredStockMember
2023-09-08
0001481028
hysr:TwoZeroOneNineEquityIncentivePlanMember
us-gaap:StockOptionMember
2018-12-17
0001481028
hysr:TwoZeroOneNineEquityIncentivePlanMember
2018-12-17
2018-12-17
0001481028
hysr:TwoZeroOneNineEquityIncentivePlanMember
2024-07-01
2024-12-31
0001481028
hysr:TwoZeroOneNineEquityIncentivePlanMember
2024-12-31
0001481028
hysr:TwentyZeroTwoTwoEquityStockIncentivePlanMember
hysr:EquityIncentiveMember
2022-01-27
2022-01-27
0001481028
hysr:TwentyZeroTwoTwoEquityStockIncentivePlanMember
2022-01-27
2022-01-27
0001481028
hysr:TwentyZeroTwoTwoEquityStockIncentivePlanMember
2024-07-01
0001481028
hysr:TwentyZeroTwoTwoEquityStockIncentivePlanMember
2024-07-01
2024-07-01
0001481028
hysr:TwentyZeroTwoTwoEquityStockIncentivePlanMember
2024-07-01
2024-12-31
0001481028
hysr:TwentyZeroTwoTwoEquityStockIncentivePlanMember
2024-12-31
0001481028
us-gaap:WarrantMember
2024-06-30
0001481028
us-gaap:WarrantMember
2024-07-01
2024-12-31
0001481028
us-gaap:WarrantMember
2024-12-31
0001481028
2022-11-01
2022-11-11
0001481028
2022-11-11
0001481028
2024-05-24
2024-05-24
0001481028
hysr:TECOBondsMember
2024-05-24
2024-05-24
0001481028
hysr:TECOBondsMember
us-gaap:InvestorMember
2024-05-24
2024-05-24
0001481028
hysr:TECOBondsMember
2024-09-10
0001481028
2024-09-10
0001481028
hysr:TECOMember
2024-09-30
0001481028
hysr:TECOMember
2024-12-31
0001481028
hysr:NovemberTwentFourTwoThousandTwentyTwoMember
hysr:TECOMember
2024-12-31
0001481028
hysr:NovemberTwentFourTwoThousandTwentyTwoMember
hysr:TECOMember
2024-06-30
0001481028
hysr:NovemberTwentFourTwoThousandTwentyTwoMember
hysr:TECOMember
2024-07-01
2024-12-31
0001481028
hysr:MayTwentyFourTwoThousandTwentyFourMember
hysr:TECOMember
2024-12-31
0001481028
hysr:MayTwentyFourTwoThousandTwentyFourMember
hysr:TECOMember
2024-06-30
0001481028
hysr:MayTwentyFourTwoThousandTwentyFourMember
hysr:TECOMember
2024-07-01
2024-12-31
0001481028
hysr:TECOMember
2024-12-31
0001481028
hysr:TECOMember
2024-06-30
0001481028
hysr:TECOMember
2024-07-01
2024-12-31
0001481028
hysr:InterestEarnedOnCashMember
2024-07-01
2024-12-31
0001481028
hysr:InterestEarnedOnCashMember
2023-07-01
2023-12-31
0001481028
hysr:InterestEarnedOnTreasuryBillsMember
2024-07-01
2024-12-31
0001481028
hysr:InterestEarnedOnTreasuryBillsMember
2023-07-01
2023-12-31
0001481028
hysr:InterestEarnedOnCertificatesOfDepositMember
2024-07-01
2024-12-31
0001481028
hysr:InterestEarnedOnCertificatesOfDepositMember
2023-07-01
2023-12-31
0001481028
hysr:InterestEarnedOnCorporateBondsMember
2024-07-01
2024-12-31
0001481028
hysr:InterestEarnedOnCorporateBondsMember
2023-07-01
2023-12-31
0001481028
hysr:InterestEarnedOnTECOBondMember
2024-07-01
2024-12-31
0001481028
hysr:InterestEarnedOnTECOBondMember
2023-07-01
2023-12-31
0001481028
hysr:DividendsAndOtherMember
2024-07-01
2024-12-31
0001481028
hysr:DividendsAndOtherMember
2023-07-01
2023-12-31
0001481028
2023-09-12
0001481028
us-gaap:CertificatesOfDepositMember
2023-09-12
0001481028
us-gaap:CertificatesOfDepositMember
2023-07-01
2023-12-31
0001481028
hysr:UniversityOfIowaMember
2024-10-01
0001481028
hysr:UniversityOfIowaMember
2024-10-01
2024-10-01
0001481028
hysr:UniversityOfIowaMember
2024-12-31
2024-12-31
0001481028
hysr:UniversityOfMichiganMember
2024-10-01
0001481028
hysr:UniversityOfMichiganMember
2024-07-01
2024-12-31
0001481028
2024-04-01
0001481028
srt:ChiefExecutiveOfficerMember
us-gaap:RelatedPartyMember
2022-12-31
0001481028
2022-07-01
2022-12-31
0001481028
hysr:LoanMember
2022-07-01
2022-12-31
0001481028
hysr:LoanMember
2024-07-01
2024-12-31
0001481028
hysr:LoanMember
2023-07-01
2024-06-30
0001481028
hysr:LoanMember
2023-07-01
2023-12-31
xbrli:shares
iso4217:USD
xbrli:pure
iso4217:USD
xbrli:shares
iso4217:NOK
xbrli:shares
iso4217:NOK
In connection with the Quarterly
Report of SunHydrogen, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended December 31, 2024 as filed with the
Securities and Exchange Commission the date hereof (the “Report”), I, Timothy Young, Chief Executive Officer & Acting
Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley
Act of 2002, that: